Physician profile
Michael H Press
NPI 1497783765
$3,527.88
in general payments reported to CMS, 2019-2025
28 companies · $603 in 2025
The $603 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $98.37 · 2021: $271 · 2022: $516 · 2023: $1,043 · 2024: $816 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,420 · Education: $42.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,420.01 |
| Education | $42.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $397.09 | 2019-2023 | Krystexxa |
| Nxstage Medical, INC. | $305.66 | 2023-2024 | Nxstage System One |
| Travere Therapeutics, INC. | $266.95 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $263.64 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $234.18 | 2022-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $230.49 | 2021-2025 | Acthar, Terlivaz |
| Outset Medical INC | $224.29 | 2023 | |
| Fresenius USA Marketing, INC. | $192.65 | 2019-2024 | Velphoro, Korsuva |
| Aurinia Pharma U.S., INC. | $157.55 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $157.30 | 2024-2025 | |
| Akebia Therapeutics INC | $155.14 | 2019-2024 | Vafseo |
| Glaxosmithkline, LLC. | $141.33 | 2021-2024 | Benlysta |
| Amgen INC. | $125.83 | 2020-2025 | Tavneos, Krystexxa |
| Calliditas Therapeutics US INC. | $95.30 | 2024-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $85.09 | 2019-2025 | Lokelma, Farxiga |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $66.74 | 2022-2023 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $54.85 | 2021-2025 | |
| Genzyme Corporation | $46.90 | 2023-2024 | |
| Ultragenyx Pharmaceutical INC. | $40.38 | 2021-2022 | |
| Ardelyx, INC. | $39.49 | 2024 | Ibsrela |
| Cormedix INC. | $38.43 | 2024 | Defencath |
| Scpharmaceuticals INC. | $36.23 | 2025 | |
| Opko Pharmaceuticals, LLC | $34.67 | 2019-2023 | Rayaldee |
| Vifor Pharma, INC. | $32.19 | 2019-2020 | |
| Baxter Healthcare | $29.89 | 2023 | Renal - Pd |
| Boston Scientific Corporation | $29.33 | 2025 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $24.63 | 2023 | Onpattro |
| Apellis Pharmaceuticals, INC. | $21.66 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Press listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.